TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018 (TES)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05958810 |
Recruitment Status :
Completed
First Posted : July 25, 2023
Last Update Posted : July 25, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Malaria,Falciparum Malaria Recrudescence | Drug: Artemether-lumefantrine Drug: Primaquine |
Study Type : | Observational |
Actual Enrollment : | 80 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines in 2017-2018 |
Actual Study Start Date : | January 2, 2017 |
Actual Primary Completion Date : | December 28, 2018 |
Actual Study Completion Date : | December 28, 2018 |
Group/Cohort | Intervention/treatment |
---|---|
Patients detected with Plasmodium falciparum (Artemether-lumefantrine)
Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
|
Drug: Artemether-lumefantrine
Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined. Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to <16kg); 2 tablets (15 to <25kg); 3 tablets (25 to <35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old) Other Name: Coartem Drug: Primaquine For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days. |
- Number of Patients with Early Treatment Failure (ETF) [ Time Frame: Day 1-3 ]
The number of patients with the following criteria based on microscopy results without PCR:
- Development of danger signs or severe malaria on day 1, day 2, or day 3 in the presence of parasitemia;
- Parasitaemia on day 2 higher than day 0 count irrespective of axillary temperature;
- Parasitaemia on day 3 with axillary temperature ≥37.5 ºC;
- Parasitaemia on day 3 ≥25% of count on day 0.
- Late Clinical Failure (LCF) [ Time Frame: Day 4-28 ]
The number of patients with the following criteria based on microscopy results without PCR:
- Development of danger signs or severe malaria on any day from day 4 to day 28 in the presence of parasitemia, without previously meeting any of the criteria of Early Treatment Failure;
- Presence of parasitemia and axillary temperature ≥37.5 ºC (or history of fever in low/moderate transmission areas) on any day from day 4 to day 28, without previously meeting any of the criteria of Early Treatment Failure.
- Number of Patients with Late Parasitological Failure (LPF) [ Time Frame: Day 7-28 ]The number of patients with the presence of parasitemia on any day from day 7 to day 28 and axillary temperature <37.5 ºC, without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure.
- Number of Patients with Adequate Clinical and Parasitological Response (ACPR) [ Time Frame: Day 0-28 ]The number of patients with absence of parasitemia on day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 59 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Above 6 months old to 59 years old;
- Mono-infection with P. falciparum (1000-100 000 asexual forms per µl)
- Axillary temperature ≥37.5 °C or oral/rectal temperature of ≥38 °C;
- Ability to swallow medication;
- Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- Informed consent from the patient or from a parent or legal guardian in the case of children less than 18 years old;
- Informed assent from any minor participant aged 12 - 17 years;
- Consent for pregnancy testing from females of child-bearing potential and from their parent or guardian if under 18 years old.
Exclusion Criteria:
- Presence of general danger signs among children <5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions
- Mixed Plasmodium species;
- Presence of severe malnutrition
- Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, HIV/AIDS)
- History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05958810
Principal Investigator: | Fe Esperanza Caridad J Espino, MD, PhD | Research Institute for Tropical Medicine |
Documents provided by Fe Espino, Research Institute for Tropical Medicine, Philippines:
Responsible Party: | Fe Espino, Medical Specialist IV, Principal Investigator, Head of Parasitology Department, Research Institute for Tropical Medicine, Philippines |
ClinicalTrials.gov Identifier: | NCT05958810 |
Other Study ID Numbers: |
2003-25-12_2017 |
First Posted: | July 25, 2023 Key Record Dates |
Last Update Posted: | July 25, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The IPD will be shared with Data Transfer Agreement and IRB Approval |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | Data information will be provided upon request |
Access Criteria: | Data Transfer |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Malaria TES Artemether-lumefantrine |
Malaria Malaria, Falciparum Recurrence Protozoan Infections Parasitic Diseases Infections Mosquito-Borne Diseases Vector Borne Diseases Disease Attributes |
Pathologic Processes Lumefantrine Artemether Primaquine Artemether, Lumefantrine Drug Combination Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents |